跳至主要内容
临床试验/JPRN-UMIN000008808
JPRN-UMIN000008808已完成未知

Exploratory study for biomarkers to predict efficacy and toxicity to Sorafenib in patients with advanced hepatocellular carcinoma - Biomarker study of sorafenib

ational Cancer Center Hospital0 个研究点目标入组 100 人开始时间: 2012年9月1日最近更新:
适应症

试验速览

阶段
未知
状态
已完成
入组人数
100

研究概览

简要总结

暂无简介。

研究设计

研究类型
Observational

入排标准

年龄范围
ot applicable 至 ot applicable(—)
性别
All

入选标准

  • 未提供

排除标准

  • 1. Ineligible for dynamic CT or MRI; 2. Patients with cerebral metastasis; 3. Pregnant and breastfeeding women or those who may possibly be pregnant; 4. Patients with uncontrollable hypertension (BP>170 mmHg under medication) or with thromboembolism, ischemic heart disease, unstable angina pectoris, heart failure, or cerebrovascular disorder; 5. Patients with moderate or severe renal dysfunction (Ccr < 30 mL/min) including those on dialysis; 6. Patients with esophageal varices that may cause bleeding (those who had gastrointestinal bleeding in the past month); 7. Patients under treatment with drugs affecting the activity of CYP3A4 or UGT1A9 (e.g., carbamazepine, rifampicin, St. John's wort, etc. ) or drugs that may affect the serum concentration of sorafenib; 8. Patients with diseases related to human immunodeficiency virus (HIV) or acquired immunodeficiency syndrome (AIDS); or 9. Patients judged as ineligible by the investigator in charge for other reasons

研究者

相似试验

Exploratory study for biomarkers to predict efficacy... | 临床试验